高剂量N-乙酰半胱氨酸长期治疗早期慢性阻塞性肺疾病(GOLD I-II期):中国多中心、双盲、平行组、随机对照试验的研究方案
本研究为在中国24个中心开展的多中心、双盲、安慰剂对照、平行组随机对照试验,评估高剂量N-乙酰半胱氨酸(600 mg每日两次)长期治疗早期COPD(GOLD I-II期)患者的疗效与安全性。研究对象为40-80岁患者,随机接受NAC或安慰剂治疗2年,主要测量指标包括FEV1、COPD急性加重次数、健康相关生活质量和药物经济学分析。该试验旨在为早期COPD管理提供循证依据。
要点
- 高剂量NAC(600 mg每日两次)长期治疗早期COPD(GOLD I-II期)的疗效与安全性尚缺乏随机对照试验证据。
- 该试验在中国24个中心开展,纳入40-80岁早期COPD患者,随机双盲安慰剂对照治疗2年。
- 主要评估指标包括FEV1、急性加重次数、健康相关生活质量及药物经济学分析。
核心结论
- 目前尚无高剂量N-乙酰半胱氨酸(600 mg每日两次)用于轻中度COPD(GOLD I-II期)患者的随机对照试验,本试验旨在评估其有效性、安全性和成本效益。
研究设计与样本
- 多中心、双盲、安慰剂对照、平行组随机对照试验,在中国24个中心开展。
- 研究对象为40-80岁早期COPD患者,由经过专门培训的医师或研究者招募。
- 受试者随机分配至NAC 600 mg每日两次组或匹配安慰剂组,治疗2年。
关键数值与推荐
- 干预方案:NAC 600 mg每日两次,对照组为匹配安慰剂,疗程2年。
- 评估指标包括FEV1、COPD急性加重次数、健康相关生活质量和药物经济学分析。
- 试验注册号:Chinese Clinical Trial Registry ChiCTR-IIR-17012604,注册日期2017年9月7日。
临床怎么用
- 该试验结果可能指导临床实践并改变早期COPD的管理标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The presence of increased oxidative stress and airway inflammation has been proven in subjects with chronic obstructive pulmonary disease (COPD). Several studies have demonstrated that drugs with antioxidant and anti-inflammatory properties such as N-acetylcysteine (NAC) can reduce the rate of exacerbations in patients with COPD. However, the beneficial effects of NAC in early-stage COPD are minimally discussed. We are investigating whether high-dose NAC has therapeutic effects in Chinese patients with early-stage COPD. METHOD AND ANALYSIS: A randomized, double-blinded, placebo-controlled, parallel-group, multicenter clinical trial is evaluating the efficacy and safety of NAC for the long-term treatment of patients with early-stage COPD at 24 centers in China. Subjects aged 40-80 years and recruited by physicians or researchers with special training will be randomized to either NAC 600 mg twice daily group or matching placebo group for 2 years. Measurements will include forced expiratory volume in 1 s (FEV1), the number of COPD exacerbations, health-related quality, and pharmacoeconomic analysis. DISCUSSION: Currently, there are no randomized controlled trials with high-dose N-acetylcysteine (600 mg twice daily) for patients with mild-to-moderate COPD (GOLD I-II). We designed this multicenter randomized controlled trial (RCT) to assess the effectiveness, safety, and cost-effectiveness of long-term treatment with high-dose N-acetylcysteine. The results of this trial may guide clinical practice and change the standard of early COPD management. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-IIR-17012604 . Registered on 07 September 2017.
引用
- Tian H, Zhou Y, Tang L, et al. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China. Trials. 2020. PMID: 32917271. doi:10.1186/s13063-020-04701-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。